ASCO/EHA/ICML 2021 – Alvaro Alencar
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationAlvaro Alencar discusses which first-line treatment options might soon be established for newly diagnosed patients with mantle cell lymphoma who are not eligible for intensive therapy, what can be expected in terms of innovative approaches in the setting of R/R mantle cell lymphoma or marginal zone lymphoma and highlights the need for robust prognostic tools allowing stratification of treatment modalities.
Here is the full ASCO/EHA/ICML 2021 report.
More posts
Preface – ASCO/EHA/ICML 2021
As virtual scientific conferences are becoming part of our daily routine as clinicians and researchers, information in individual areas of interest is easily accessible across different congresses.